Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

5-HT(2C) receptor activation is a common mechanism on proerectile effects of apomorphine, oxytocin and melanotan-II in rats.

Kimura Y, Naitou Y, Wanibuchi F, Yamaguchi T.

Eur J Pharmacol. 2008 Jul 28;589(1-3):157-62. doi: 10.1016/j.ejphar.2008.05.022. Epub 2008 May 24.

PMID:
18582863
2.

Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.

Shimada I, Maeno K, Kondoh Y, Kaku H, Sugasawa K, Kimura Y, Hatanaka K, Naitou Y, Wanibuchi F, Sakamoto S, Tsukamoto S.

Bioorg Med Chem. 2008 Mar 15;16(6):3309-20. Epub 2007 Dec 8.

PMID:
18083579
3.

Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists.

Shimada I, Maeno K, Kazuta K, Kubota H, Kimizuka T, Kimura Y, Hatanaka K, Naitou Y, Wanibuchi F, Sakamoto S, Tsukamoto S.

Bioorg Med Chem. 2008 Feb 15;16(4):1966-82. Epub 2007 Nov 4.

PMID:
18035544
4.

Characterization of intracavernous pressure increase induced by Ym348, a novel 5-HT2C receptor agonist, in anesthetized rats.

Kimura Y, Naitou Y, Wanibuchi F, Yamaguchi T.

J Urol. 2006 May;175(5):1953-7. Erratum in: J Urol. 2006 Jul;176(1):414.

PMID:
16600805
5.

Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist.

Kimura Y, Hatanaka K, Naitou Y, Maeno K, Shimada I, Koakutsu A, Wanibuchi F, Yamaguchi T.

Eur J Pharmacol. 2004 Jan 1;483(1):37-43. Erratum in: Eur J Pharmacol. 2004 Feb 23;486(3):353.

PMID:
14709324
6.

Allodynia and hyperalgesia in adjuvant-induced arthritic rats: time course of progression and efficacy of analgesics.

Nagakura Y, Okada M, Kohara A, Kiso T, Toya T, Iwai A, Wanibuchi F, Yamaguchi T.

J Pharmacol Exp Ther. 2003 Aug;306(2):490-7. Epub 2003 May 1.

7.

Phencyclidine-induced abnormal behaviors in rats as measured by the hole board apparatus.

Morita T, Sonoda R, Nakato K, Koshiya K, Wanibuchi F, Yamaguchi T.

Psychopharmacology (Berl). 2000 Feb;148(3):281-8.

PMID:
10755741
8.

Synthesis and pharmacological characterization of novel 6-fluorochroman derivatives as potential 5-HT1A receptor antagonists.

Yasunaga T, Kimura T, Naito R, Kontani T, Wanibuchi F, Yamashita H, Nomura T, Tsukamoto S, Yamaguchi T, Mase T.

J Med Chem. 1998 Jul 16;41(15):2765-78.

PMID:
9667967
9.

Synthesis and structure-activity studies of a series of 1-oxa-2,8-diazaspiro[4.5]decan-3-ones and related compounds as M1 muscarinic agonists.

Tsukamoto S, Nagaoka H, Igarashi S, Wanibuchi F, Hidaka K, Tamura T.

Chem Pharm Bull (Tokyo). 1995 Sep;43(9):1523-9.

PMID:
7586076
10.

Synthesis and structure-activity studies of a series of 1-oxa-8-azaspiro[4.5]decanes as M1 muscarinic agonists.

Tsukamoto S, Fujii M, Yasunaga T, Matsuda K, Wanibuchi F, Hidaka K, Furuya T, Tamura T.

Chem Pharm Bull (Tokyo). 1995 May;43(5):842-52.

PMID:
7553970
11.

Characterization of a novel muscarinic receptor agonist, YM796: comparison with cholinesterase inhibitors in in vivo pharmacological studies.

Wanibuchi F, Nishida T, Yamashita H, Hidaka K, Koshiya K, Tsukamoto S, Usuda S.

Eur J Pharmacol. 1994 Nov 24;265(3):151-8.

PMID:
7875230
12.
13.

Pharmacological characterization of a novel muscarinic partial agonist, YM796, in transfected cells expressing the m1 or m2 muscarinic receptor gene.

Wei HB, Roeske WR, Lai J, Wanibuchi F, Hidaka K, Usuda S, Yamamura HI.

Life Sci. 1992;50(5):355-63.

PMID:
1310135
14.

Pharmacological studies on novel muscarinic agonists, 1-oxa-8-azaspiro[4.5]decane derivatives, YM796 and YM954.

Wanibuchi F, Konishi T, Harada M, Terai M, Hidaka K, Tamura T, Tsukamoto S, Usuda S.

Eur J Pharmacol. 1990 Oct 23;187(3):479-86.

PMID:
1963596
15.

Synergistic effects between D-1 and D-2 dopamine antagonists on catalepsy in rats.

Wanibuchi F, Usuda S.

Psychopharmacology (Berl). 1990;102(3):339-42.

PMID:
1979179

Supplemental Content

Loading ...
Support Center